This post was published on ZYX Short Sell Change Alert The stock is likely to be very volatile, conservative investors should not enter this trade.  The results of the trial are being misinterpreted by some in the market. Here are the details. LLY announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer’s disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer’s disease. In

This post was published on ZYX Short Sell Change Alert Stock moved right after the post. Most fills should be $43.87. Consider adding 10% around $43.80-44.50.

This post was published on ZYX Short Sell Change Alert LLY Alzheimer drug trial has failed. Consider starting a 10% tranche right here around $42.82. More later.